{"ctNumber":"2023-505430-10-00","ctStatus":"Authorised","startDateEU":"2024-10-10","decisionDate":"2023-12-21T10:38:44.655","publishDate":"2026-03-19T02:32:08.844353511","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":120858,"rowSubjectCount":0,"products":[{"id":501037,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10008562","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD10008562","prodAuthStatus":1,"prodName":"Flortaucipir","pharmForm":"SOLUTION FOR INJECTION","sponsorProductCode":"LY3191748","activeSubstanceName":"FLORTAUCIPIR (18F)","euSubstNumber":"SUB194115","nameOrg":"ELI LILLY AND COMPANY LIMITED","productSubstances":[{"productPk":"10008562","substancePk":"283539","nameOrg":"ELI LILLY AND COMPANY LIMITED","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"FLORTAUCIPIR (18F)","substanceEvCode":"SUB194115"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq/Aµg megabecquerel(s)/microgram","maxDailyDoseAmount":"370","doseUomTotal":"MBq/Aµg megabecquerel(s)/microgram","maxTotalDoseAmount":"370","maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD10008562","sponsorProductCodeEdit":"LY3191748","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS BOLUS INJECTION/IV INFUSION"],"allSubstancesChemicals":true,"productName":"Flortaucipir","jsonActiveSubstanceNames":"flortaucipir (18f)","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"The clinical value of tau PET in the memory clinic (TAP-TAU)","fullTitleTranslations":[],"publicTitle":"TAP-TAU","publicTitleTranslations":[],"secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"10","trialCategory":"2","justificationForTrialCategory":"Our study does not fall into a trial category strictly speaking","trialCategoryId":110814},"medicalCondition":{"partIMedicalConditions":[{"id":125765,"medicalCondition":"Mild cognitive impairment and dementia","medicalConditionTranslations":[],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"1","trialScopeId":365897}],"mainObjective":"To assess the value of tau PET as a diagnostic tool in clinical practice in order to improve diagnostic accuracy, patient management and patient wellbeing.","mainObjectiveTranslations":[],"secondaryObjectives":[{"id":425548,"number":1,"secondaryObjective":"To compare the diagnostic performance of tau PET against (combinations of) less expensive and more accessible diagnostic tools","secondaryObjectiveTranslations":[]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":813383,"number":1,"principalInclusionCriteria":"Patients 50 years or older","principalInclusionCriteriaTranslations":[]},{"id":813384,"number":2,"principalInclusionCriteria":"Prodromal (i.e. MCI) stage, in which individuals have subjective and/or objective cognitive impairment and a CDR score of 0.5 or mild dementia stage, in which individuals have a CDR score of 1","principalInclusionCriteriaTranslations":[]},{"id":813385,"number":3,"principalInclusionCriteria":"Completed routine work-up including at least basic cognitive screening tests and MRI scanning with a 3DT1 sequence","principalInclusionCriteriaTranslations":[]},{"id":813386,"number":4,"principalInclusionCriteria":"After routine dementia screening, there is substantial diagnostic uncertainty (<85%) due to i) suspicion of mixed pathology, ii) presence of an atypical clinical presentation, and/or iii) conflicting/inconclusive information from other diagnostic tests like MRI or CSF. AD is in the differential diagnosis.","principalInclusionCriteriaTranslations":[]},{"id":813387,"number":5,"principalInclusionCriteria":"Subjects must, in the opinion of the attending neurologist be able to tolerate study procedures (only for the tau PET participants) and be competent to make a well-informed decision to participate in this study","principalInclusionCriteriaTranslations":[]}],"principalExclusionCriteria":[{"id":1392282,"number":1,"principalExclusionCriteria":"Cognitively normal (defined as no objective cognitive deficits at neuropsychological testing and a Clinical Dementia rating scale (CDR) score of 0) or advanced dementia stage (defined as CDR > 1).","principalExclusionCriteriaTranslations":[]},{"id":1392283,"number":2,"principalExclusionCriteria":"Has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with the clinical presentation and/or interpretation of PET scan","principalExclusionCriteriaTranslations":[]},{"id":1392284,"number":3,"principalExclusionCriteria":"Is a woman of childbearing potential who is not surgically sterile, not refraining from sexual activity or not using reliable methods for contraception. Women of childbearing potential must confirm not to be pregnant or breast feeding at screening; (only for tau PET participants)","principalExclusionCriteriaTranslations":[]},{"id":1392285,"number":4,"principalExclusionCriteria":"Has a relevant history of severe drug allergy or hypersensitivity. Relevant severe drug allergies should be determined by the locally appointed coordinating researcher (only for tau PET participants)","principalExclusionCriteriaTranslations":[]},{"id":1392286,"number":5,"principalExclusionCriteria":"Has ever been treated with an anti-amyloid drug or tau agent (only for tau PET participants)","principalExclusionCriteriaTranslations":[]},{"id":1392287,"number":6,"principalExclusionCriteria":"History of any clinically significant cardiovascular, endocrinology, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic (with the exception of AD), psychiatric, renal or other major disease, as determined by the principal investigator","principalExclusionCriteriaTranslations":[]},{"id":1392288,"number":7,"principalExclusionCriteria":"Has been injected with a previously administered radiopharmaceutical within 6 terminal half-lives or when total yearly radiation exposure for research exceeds 11.3 mSv for females and 15.3 mSv for males. (only for tau PET participants)","principalExclusionCriteriaTranslations":[]},{"id":1392289,"number":8,"principalExclusionCriteria":"Is a member of the study team, an employee of the department of Radiology and Nuclear medicine or the department of Neurology in any of the sites or is related to an employee of the department of Radiology and Nuclear medicine or the department of Neurology in any of the sites.","principalExclusionCriteriaTranslations":[]}]},"endPoint":{"primaryEndPoints":[{"id":952929,"number":1,"endPoint":"Pre- vs. post-tau PET change in diagnosis (diagnostic categories: AD, non-AD with specification of suspected underlying pathology, mixed AD/non-AD pathology) and comparison with a control group after a year","isPrimary":true,"endPointTranslations":[]},{"id":952930,"number":2,"endPoint":"Pre- vs. post-tau PET change in confidence of the clinician in the etiological diagnosis (continuous scale ranging from 0-100%, baseline <85% required) and comparison with a control group after a year.","isPrimary":true,"endPointTranslations":[]},{"id":952931,"number":3,"endPoint":"Pre- vs. post-tau PET change in patient management (increase or reduction in ancillary investigations, initiation or withdrawal of medication, initiation or withdrawal of care; we will also assess whether it would influence hypothetical prescription of disease modifying treatment of AD) and comparison with a control group after a year.","isPrimary":true,"endPointTranslations":[]},{"id":952932,"number":4,"endPoint":"Pre- vs. post-tau PET change in patient wellbeing (measures of anxiety and uncertainty) and behavioural intentions and post-tau PET perceptions, experiences and understanding of tau PET.","isPrimary":true,"endPointTranslations":[]}],"secondaryEndPoints":[{"id":952933,"number":1,"endPoint":"Performance of tau PET compared to novel blood-based biomarkers and artificial intelligence (AI) based classifiers.","isPrimary":false,"endPointTranslations":[]}]},"trialDuration":{"estimatedEndDate":"2026-12-01","estimatedRecruitmentStartDate":"2023-12-01"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":331948,"ageRangeCategoryCode":"4","ageRangeCategory":"4"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-18","conclusionDate":"2026-03-18","therapeuticAreas":[{"code":"10","name":"Diseases [C] - Nervous System Diseases [C10]"}],"medicalConditions":[{"id":125765,"medicalCondition":"Mild cognitive impairment and dementia","isConditionRareDisease":false}],"sponsors":[{"id":136873,"primary":true,"publicContacts":[{"id":403503,"type":"Public","functionalName":"Marie Vermeiren","functionalEmailAddress":"m.r.vermeiren@amsterdamumc.nl","telephone":"+31204449298","organisation":{"id":127768,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":403504,"type":"Scientific","functionalName":"Marie Vermeiren","functionalEmailAddress":"m.r.vermeiren@amsterdamumc.nl","telephone":"+31204449298","organisation":{"id":127768,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":127768,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"},"addresses":[{"id":124762,"organisation":{"id":127768,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"},"address":{"addressId":131276,"oneLine":"De Boelelaan 1117","addressLine1":"De Boelelaan 1117","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1081 HV","country":2029,"countryName":"Netherlands"},"email":"ctis&#64;amsterdamumc.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100013880"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Our study does not fall into a trial category strictly speaking","partOneTherapeuticAreas":[{"id":1100030,"therapeuticArea":{"code":"10","name":"Diseases [C] - Nervous System Diseases [C10]"}}],"productRoleGroupInfos":[{"id":374698,"comments":"Flortaucipir","productRoleCode":"1","productRoleName":"Test","products":[{"id":501037,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10008562","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD10008562","prodAuthStatus":1,"prodName":"Flortaucipir","pharmForm":"SOLUTION FOR INJECTION","sponsorProductCode":"LY3191748","activeSubstanceName":"FLORTAUCIPIR (18F)","euSubstNumber":"SUB194115","nameOrg":"ELI LILLY AND COMPANY LIMITED","productSubstances":[{"productPk":"10008562","substancePk":"283539","nameOrg":"ELI LILLY AND COMPANY LIMITED","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"FLORTAUCIPIR (18F)","substanceEvCode":"SUB194115"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"MBq/Aµg megabecquerel(s)/microgram","maxDailyDoseAmount":"370","doseUomTotal":"MBq/Aµg megabecquerel(s)/microgram","maxTotalDoseAmount":"370","maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD10008562","sponsorProductCodeEdit":"LY3191748","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS BOLUS INJECTION/IV INFUSION"],"allSubstancesChemicals":true,"productName":"Flortaucipir","jsonActiveSubstanceNames":"flortaucipir (18f)","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":286514,"mscId":14140,"mscInfo":{"id":14140,"clinicalTrialId":5763,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2023-12-05","toDate":"2023-12-05","isProposedRms":true,"countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2023-12-21","trialStatus":"Authorised","trialPeriod":[{"id":44712,"trialStartDate":"2024-10-10","fromDate":"2024-12-03"},{"id":44713,"trialStartDate":"2024-10-10","fromDate":"2024-12-03"},{"id":44714,"trialStartDate":"2024-10-10","fromDate":"2024-12-03"}],"trialRecruitmentPeriod":[{"id":91154,"recruitmentStartDate":"2024-10-10","fromDate":"2025-10-27"},{"id":91155,"recruitmentStartDate":"2024-10-10","fromDate":"2025-10-27"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":61015,"trialStartDate":"2024-10-10","fromDate":"2024-12-03"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-10"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":12202,"mscId":14140,"trialStatus":"Under evaluation","trialStatusDate":"2023-09-12T16:28:25.624"},{"id":19564,"mscId":14140,"trialStatus":"Authorised","trialStatusDate":"2023-12-21T10:38:44.347"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-18","decision":"authorized_conditions","decisionDate":"2023-12-21"},"decisionDate":"2023-12-21","recruitmentSubjectCount":360,"trialSites":[{"id":1972986,"organisationAddressInfo":{"id":925479,"organisation":{"id":968400,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Spaarne Gasthuis Stichting","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100021671","organisationLocationStatus":"Active"},"address":{"addressId":1037344,"oneLine":"Boerhaavelaan 24","addressLine1":"Boerhaavelaan 24","addressLine2":"","addressLine3":"","addressLine4":"","city":"Haarlem","postcode":"2035 RC","country":2029,"countryName":"Netherlands"},"phone":"0031232240000","email":"schoonenboom@spaarnegasthuis.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100021671"},"personInfo":{"id":2191481,"firstName":"Niki","lastName":"Schoonenboom","telephone":"0031232240000","email":"schoonenboom@spaarnegasthuis.nl"},"departmentName":"Neurology"},{"id":1972958,"organisationAddressInfo":{"id":202964,"organisation":{"id":206567,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Groningen","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022118","organisationLocationStatus":"Active"},"address":{"addressId":215831,"oneLine":"Hanzeplein 1","addressLine1":"Hanzeplein 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Groningen","postcode":"9713 GZ","country":2029,"countryName":"Netherlands"},"phone":"0503616161","email":"g.luurtsema@umcg.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100030831"},"personInfo":{"id":2191441,"firstName":"Gert","lastName":"Luurtsema","telephone":"0503616161","email":"g.luurtsema@umcg.nl","title":"2"},"departmentName":"Radiology and Nuclear Medicine"},{"id":1972956,"organisationAddressInfo":{"id":202966,"organisation":{"id":206569,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Medisch Centrum Leeuwarden B.V.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042953","organisationLocationStatus":"Active"},"address":{"addressId":215833,"oneLine":"Henri Dunantweg 2","addressLine1":"Henri Dunantweg 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Leeuwarden","postcode":"8934 AD","country":2029,"countryName":"Netherlands"},"phone":"582866666","email":"Wetenschap@mclacademie.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100071016"},"personInfo":{"id":2191439,"firstName":"Niek","lastName":"Verwey","telephone":"582866666","email":"Wetenschap@mclacademie.nl","title":"1"},"departmentName":"Neurology"},{"id":1972955,"organisationAddressInfo":{"id":202967,"organisation":{"id":206570,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitair Medisch Centrum Utrecht","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008351","organisationLocationStatus":"Active"},"address":{"addressId":215834,"oneLine":"Heidelberglaan 100","addressLine1":"Heidelberglaan 100","addressLine2":"","addressLine3":"","addressLine4":"","city":"Utrecht","postcode":"3584 CX","country":2029,"countryName":"Netherlands"},"phone":"0887555555","email":"n.tolboom@umcu.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100014822"},"personInfo":{"id":2191438,"firstName":"Nelleke","lastName":"Tolboom","telephone":"0887555555","email":"n.tolboom@umcu.nl","title":"1"},"departmentName":"Radiology and Nuclear Medicine"},{"id":1972959,"organisationAddressInfo":{"id":202955,"organisation":{"id":206558,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008976","organisationLocationStatus":"Active"},"address":{"addressId":215822,"oneLine":"Dr. Molewaterplein 60","addressLine1":"Dr. Molewaterplein 60","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rotterdam","postcode":"3015 GJ","country":2029,"countryName":"Netherlands"},"phone":"0107040704","email":"m.vernooij@erasmusmc.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100016820"},"personInfo":{"id":2191442,"firstName":"Meike","lastName":"Vernooij","telephone":"0107040704","email":"m.vernooij@erasmusmc.nl","title":"2"},"departmentName":"Radiology and Nuclear Medicine"},{"id":1972957,"organisationAddressInfo":{"id":202954,"organisation":{"id":206557,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Amsterdam UMC","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008355","organisationLocationStatus":"Active"},"address":{"addressId":215821,"oneLine":"De Boelelaan 1117","addressLine1":"De Boelelaan 1117","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1081 HV","country":2029,"countryName":"Netherlands"},"phone":"0204444444","email":"ctis@amsterdamumc.nl","isBusinessKeyValidated":true,"businessKey":"LOC-100013880"},"personInfo":{"id":2191440,"firstName":"Elsmarieke","lastName":"van de Giessen","telephone":"0204444444","email":"ctis@amsterdamumc.nl","title":"1"},"departmentName":"Radiology and Nuclear Medicine"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":7508,"type":"INITIAL","status":"Authorised","ctNumber":"2023-505430-10-00","trialStatus":"Authorised","submissionDate":"2023-09-12","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2023-12-21"},"partIIInfo":[{"id":55846,"mscId":14140,"mscInfo":{"id":14140,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2023-12-21","decision":"authorized_conditions","decisionDate":"2023-12-21","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2023-12-21"},"applicationStatusCode":"Authorised"}],"decisionDate":"2023-12-21","ctMSCsByApplication":[{"id":14140,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":10565,"applicationId":7508,"mscId":14140,"mscName":"Netherlands","decisionDate":"2023-12-21T10:38:44.655","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":55846,"part1Id":24170,"applicationType":"INITIAL","isRMS":true}]},{"id":30465,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-505430-10-00","trialStatus":"Authorised","submissionDate":"2024-07-08","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-09-06"},"partIIInfo":[],"decisionDate":"2024-09-06","ctMSCsByApplication":[{"id":14140,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":36651,"applicationId":30465,"mscId":14140,"mscName":"Netherlands","decisionDate":"2024-09-06T15:40:06.292","decision":"authorized","eventType":"decision","part1Id":48007,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":46729,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-505430-10-00","trialStatus":"Authorised","submissionDate":"2025-01-29","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-08"},"partIIInfo":[{"id":190615,"mscId":14140,"mscInfo":{"id":14140,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-08","decision":"authorized_conditions","decisionDate":"2023-12-21","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2023-12-21"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-08","ctMSCsByApplication":[{"id":14140,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":65775,"applicationId":46729,"mscId":14140,"mscName":"Netherlands","decisionDate":"2025-04-08T16:00:10.524","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":190615,"part1Id":78316,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":78886,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-505430-10-00","trialStatus":"Authorised","submissionDate":"2026-03-06","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-18"},"partIIInfo":[{"id":286514,"mscId":14140,"mscInfo":{"id":14140,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-18","decision":"authorized_conditions","decisionDate":"2023-12-21","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2023-12-21"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-03-18","ctMSCsByApplication":[{"id":14140,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":114909,"applicationId":78886,"mscId":14140,"mscName":"Netherlands","decisionDate":"2026-03-18T10:39:37.263","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":286514,"part1Id":120858,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Netherlands","mscId":14140,"firstDecisionDate":"2023-12-21T10:38:44.655","lastDecisionDate":"2026-03-18T10:39:37.263","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":14140,"mscName":"Netherlands","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-10"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-10-10"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_ Protocol 2023-505430-10-00","uuid":"1e4e2238-73ce-48f1-abb9-7df75eee830e","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"6","systemVersion":"7"},{"title":"D4_ Patient facing documents survey T0","uuid":"73a9bdbc-0cd9-4907-979b-05374b12b4ae","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"1"},{"title":"D4_ Patient facing documents survey T2","uuid":"9f353911-054d-4e9b-a036-581e9621e31a","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"1"},{"title":"D4_ Patient facing documents survey T1","uuid":"70118f04-53f3-4861-9040-631dd67e27aa","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"1"},{"title":"D4_ Patient facing documents A-IADL-Q-SV30 T3","uuid":"1776b4ad-5144-4db3-bc55-524f31434dbc","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"2","systemVersion":"2"},{"title":"D4_ Patient facing documents Geriatric Anxiety Inventory T3","uuid":"7927f722-471b-4cfe-ba95-9f6aabf21769","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"1"},{"title":"D4_ Patient facing documents Geriatric Depression Scale 15 T3","uuid":"140d0aa3-6585-4af7-9a48-547ab1f8b4c4","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"2"},{"title":"D4_ Patient facing documents Apathy Evaluatie Schaal T3","uuid":"74988a81-70bd-47f3-89df-8ecdd6c13212","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"2"},{"title":"D5_ Clinician CRF","uuid":"de1f093b-7147-44c2-a4d6-5d079cda5a47","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"2","systemVersion":"3"},{"title":"D5_ Clinician CRF_TC","uuid":"f3a66e8c-7c97-4e39-b2be-b8e4d0c37ad1","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"2","systemVersion":"1"},{"title":"D1_ Protocol 2023-505430-10-00 version 5 dd 11-03-2025_CLEAN","uuid":"81bb2d78-fceb-4e25-9f11-65fa654ef32e","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"5","systemVersion":"1"},{"title":"D1_ Protocol synopsis_NL 2023-505430-10-00","uuid":"f6a2fe77-882d-42fe-8772-da6b74e0a617","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"1"},{"title":"D1_ Protocol synopsis_ENG 2023-505430-10-00","uuid":"79685ca0-ea5f-4405-abef-a3a8e8ef5876","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":120858,"manualVersion":"1","systemVersion":"1"},{"title":"K1_ Recruitment arrangements","uuid":"750d6fe7-a9f9-48f9-8c1a-75aec8a2b943","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":286514,"manualVersion":"1","systemVersion":"1"},{"title":"L1_ SIS and ICF control group","uuid":"6633f431-9d84-404c-a039-612dd4aea229","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":286514,"manualVersion":"3","systemVersion":"4"},{"title":"L1_SIS and ICF tau PET group","uuid":"fd8f51c5-4c45-4a82-9dcd-a31a3ce3023d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":286514,"manualVersion":"6","systemVersion":"7"},{"title":"L1_Informatiebrief deelnemer ABOARD Cohort v2 dd 20230206","uuid":"17141512-348f-4e3d-908e-32ff70b3b6dc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":286514,"manualVersion":"2","systemVersion":"1"},{"title":"L1_ SIS and ICF control group version 4 dd 11-03-2025_CLEAN","uuid":"0557bb33-f94d-4445-afd3-f4fa0327f9b3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":286514,"manualVersion":"4","systemVersion":"1"},{"title":"L1_SIS and ICF tau PET group version 5 dd 11-03-2025_CLEAN","uuid":"37ba4f76-d0b3-4921-9d74-9144434661a7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":286514,"manualVersion":"5","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}